ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatment
Year: 2025
Type: article
Abstract: Paediatric mycosis fungoides (MF) is characterized by early-stage disease, a strikingly indolent course and high rates of unusual variants. Despite these clinical peculiarities and the special treatment-related safety considerations in children and adolescents, detailed published data on treatments of paediatric MF are scarce, and management is currently based primarily on standard practice in adults. The aim of this work was to develop treatment recommendations specifically designed for MF in children and adolescents, on behalf of the three largest societies for cutaneous lymphomas, the International Society for Cutaneous Lymphomas (ISCL), the European Organisation for Research and Treatment of Cancer - Cutaneous Lymphoma Tumour Group (EORTC-CLTG), and the United States Cutaneous Lymphoma Consortium (USCLC). We developed this guideline through an international expert consensus process and in accordance with the EQUATOR Network's recommendations for guideline development. A modified Delphi process was conducted, using questionnaires covering treatment modalities that are recommended by international guidelines for adult MF. Two rounds of expert feedback were conducted, with an additional one hybrid consensus meeting. Therapeutic recommendations were formulated focusing mainly on early-stage disease. These recommendations take into account disease-specific parameters with therapeutic implications, including the specific stage of the disease, the type of lesion, and the presence of the folliculotropic variant, which is commonly observed in the paediatric age group. Patient-related factors, including safety concerns specific to this young age group, were also addressed. This ISCL/EORTC-CLTG/USCLC guideline provides up-to-date age-specific practical recommendations for the treatment of MF in children and adolescents.
Source: British Journal of Dermatology
DOI: 10.1093/bjd/ljaf198
Authors: Emmilia Hodak, Iris Amitay-Laish, Martine Bagot, Maxime Battistella, Dan Ben Amitai, Antonio Cozzio, Madeleine Duvic, Katalin Ferenczi, Francine Foss, Larisa Geskin, Emmanuella Guenova, Youn H Kim, Mark Jean-Aan Koh, Montserrat Molgó, Arti Nanda, Jan P Nicolay, Tim Niehues, Pablo Ortiz-Romero, Amra Osmancevic, Evangelia Papadavid, Jong Bin Park, Pietro Quaglino, José A Sanches, Julia Scarisbrick, Maria Luisa Sulis, Rudolf Stadler, Franz Trautinger, Maarten Vermeer, Iris Wohlmuth, John A Zic, Chalid Assaf
Institutions: Tel Aviv University, Rabin Medical Center, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Schneider Children's Medical Center, Kantonsspital St. Gallen, The University of Texas MD Anderson Cancer Center, University of Connecticut, UConn Health, Yale Cancer Center, Yale University, Columbia University Irving Medical Center, Johannes Kepler University of Linz, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Stanford Medicine, Stanford University, KK Women's and Children's Hospital, Pontificia Universidad Católica de Chile, University Medical Centre Mannheim, Helios Klinikum Krefeld, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Sahlgrenska University Hospital, Region Västra Götaland, University of Gothenburg, National and Kapodistrian University of Athens, University General Hospital Attikon, Kosin University, University of Turin, Universidade de São Paulo, Hospital Universitário da Universidade de São Paulo, University Hospitals Birmingham NHS Foundation Trust, Memorial Sloan Kettering Cancer Center, Johannes Wesling Klinikum Minden, Universitätsklinikum St. Pölten, Karl Landsteiner University of Health Sciences, Leiden University Medical Center, Paracelsus Medical University, Vanderbilt University Medical Center, MSH Medical School Hamburg – University of Applied Sciences and Medical University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, Celgene, Cilag
OpenAlex ID: W4410760559